- Home
- CVAC vs SNDX Comparison
CVAC vs SNDX Comparison
Compare CVAC & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- SNDX
- Stock Information
- Founded
- CVAC 2000
- SNDX 2005
- Country
- CVAC Germany
- SNDX United States
- Employees
- CVAC N/A
- SNDX N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- CVAC Health Care
- SNDX Health Care
- Exchange
- CVAC Nasdaq
- SNDX Nasdaq
- Market Cap
- CVAC 1.2B
- SNDX 1.3B
- IPO Year
- CVAC 2020
- SNDX 2016
- Fundamental
- Price
- CVAC $5.41
- SNDX $16.42
- Analyst Decision
- CVAC Hold
- SNDX Strong Buy
- Analyst Count
- CVAC 3
- SNDX 10
- Target Price
- CVAC $6.83
- SNDX $38.40
- AVG Volume (30 Days)
- CVAC 404.4K
- SNDX 1.9M
- Earning Date
- CVAC 11-11-2025
- SNDX 11-04-2025
- Dividend Yield
- CVAC N/A
- SNDX N/A
- EPS Growth
- CVAC N/A
- SNDX N/A
- EPS
- CVAC 1.01
- SNDX N/A
- Revenue
- CVAC $599,540,810.00
- SNDX $77,933,000.00
- Revenue This Year
- CVAC N/A
- SNDX $642.36
- Revenue Next Year
- CVAC $23.83
- SNDX $108.58
- P/E Ratio
- CVAC $5.40
- SNDX N/A
- Revenue Growth
- CVAC 675.15
- SNDX 2126.66
- 52 Week Low
- CVAC $2.37
- SNDX $8.58
- 52 Week High
- CVAC $5.72
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- CVAC 53.41
- SNDX 61.98
- Support Level
- CVAC $5.33
- SNDX $14.93
- Resistance Level
- CVAC $5.45
- SNDX $15.99
- Average True Range (ATR)
- CVAC 0.03
- SNDX 0.70
- MACD
- CVAC 0.01
- SNDX 0.04
- Stochastic Oscillator
- CVAC 66.10
- SNDX 83.26
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.